117 related articles for article (PubMed ID: 26541904)
1. Low-dose metronomic chemotherapy with cisplatin enhanced immunity in a murine model of ectopic cervical cancer.
Tsai CC; Qiu JT; Tseng CW; Hsu YC
Clin Exp Pharmacol Physiol; 2016 Feb; 43(2):251-8. PubMed ID: 26541904
[TBL] [Abstract][Full Text] [Related]
2. A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma.
Levitt JM; Jian W; Lerner SP; Sonpavde G
Urol Oncol; 2013 Feb; 31(2):234-40. PubMed ID: 21723160
[TBL] [Abstract][Full Text] [Related]
3. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.
Kim MS; Sin JI
Immunology; 2005 Oct; 116(2):255-66. PubMed ID: 16162274
[TBL] [Abstract][Full Text] [Related]
4. A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice.
Tagliamonte M; Petrizzo A; Napolitano M; Luciano A; Rea D; Barbieri A; Arra C; Maiolino P; Tornesello M; Ciliberto G; Buonaguro FM; Buonaguro L
J Transl Med; 2016 Feb; 14():58. PubMed ID: 26911136
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.
Bae SH; Park YJ; Park JB; Choi YS; Kim MS; Sin JI
Clin Cancer Res; 2007 Jan; 13(1):341-9. PubMed ID: 17200373
[TBL] [Abstract][Full Text] [Related]
6. Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma.
Goh AR; Shin SP; Jung NR; Ryu CH; Eom HS; Lee JH; Choi K; Lee SJ; Jung YS
Cancer Lett; 2015 Jan; 356(2 Pt B):743-50. PubMed ID: 25449436
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
[TBL] [Abstract][Full Text] [Related]
8. Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death.
van der Sluis TC; van Duikeren S; Huppelschoten S; Jordanova ES; Beyranvand Nejad E; Sloots A; Boon L; Smit VT; Welters MJ; Ossendorp F; van de Water B; Arens R; van der Burg SH; Melief CJ
Clin Cancer Res; 2015 Feb; 21(4):781-94. PubMed ID: 25501579
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance.
Leisching G; Loos B; Botha M; Engelbrecht AM
J Transl Med; 2015 Oct; 13():328. PubMed ID: 26474854
[TBL] [Abstract][Full Text] [Related]
10. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model.
Ahn WS; Bae SM; Kim TY; Kim TG; Lee JM; Namkoong SE; Kim CK; Sin JI
Hum Gene Ther; 2003 Oct; 14(15):1389-99. PubMed ID: 14577920
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment.
Ma Y; Han J; Jiang J; Zheng Z; Tan Y; Liu C; Zhao Y
Life Sci; 2020 Dec; 262():118565. PubMed ID: 33038371
[TBL] [Abstract][Full Text] [Related]
12. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts.
Tseng CW; Trimble C; Zeng Q; Monie A; Alvarez RD; Huh WK; Hoory T; Wang MC; Hung CF; Wu TC
Cancer Immunol Immunother; 2009 May; 58(5):737-48. PubMed ID: 18815785
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.
Kendrick JE; Straughn JM; Oliver PG; Wang W; Nan L; Grizzle WE; Stockard CR; Alvarez RD; Buchsbaum DJ
Gynecol Oncol; 2008 Mar; 108(3):591-7. PubMed ID: 18177927
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
15. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.
Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA
Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel immunogenic human leukocyte antigen-A 2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer.
Jang S; Kim YT; Chung HW; Lee KR; Lim JB; Lee K
Cancer; 2012 Apr; 118(8):2173-83. PubMed ID: 21918960
[TBL] [Abstract][Full Text] [Related]
17. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
[TBL] [Abstract][Full Text] [Related]
18. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.
Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK
Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254
[TBL] [Abstract][Full Text] [Related]
19. CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination.
Cheng WF; Hung CF; Lin KY; Ling M; Juang J; He L; Lin CT; Wu TC
Gene Ther; 2003 Aug; 10(16):1311-20. PubMed ID: 12883527
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
Cheng WF; Lee CN; Chang MC; Su YN; Chen CA; Hsieh CY
Mol Ther; 2005 Nov; 12(5):960-8. PubMed ID: 15979942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
